Daily Compared with 8-hour Gentamicin for the Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial
Overview
Authors
Affiliations
Objective: To assess whether daily gentamicin is as effective as 8-hour gentamicin for the treatment of intrapartum chorioamnionitis.
Methods: Women with a clinical diagnosis of chorioamnionitis between 32 and 42 weeks of gestation were randomly assigned in labor to receive either daily gentamicin (5 mg/kg intravenously (IV), then 2 placebo doses IV after 8 and 16 hours) or 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours). Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses). Patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses). The primary outcome was treatment success, defined by resolution of chorioamnionitis after 16 hours of treatment without development of endometritis. One hundred twenty-six patients were required to have 95% confidence that daily gentamicin is at worst 15% inferior to 8-hour dosing with an alpha of .05 and a beta of 0.2.
Results: One hundred twenty-six women were enrolled, of whom 63 received daily gentamicin and 63 received 8-hour gentamicin. One patient was excluded from data analysis. Baseline maternal and obstetric characteristics were similar between groups except for longer mean duration of ruptured membranes in the 8-hour group (679+/-514 compared with 469+/-319 minutes; P =.03). Treatment success was equal between groups (94% daily gentamicin compared with 89% 8-hour gentamicin, P =.53). There were no differences in maternal or neonatal morbidities, including neonatal sepsis and newborn hearing screen.
Conclusion: Daily and 8-hour gentamicin appear equally effective for the treatment of intrapartum chorioamnionitis.
Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00185991.
Level Of Evidence: I.
Clinical chorioamnionitis at term: definition, pathogenesis, microbiology, diagnosis, and treatment.
Jung E, Romero R, Suksai M, Gotsch F, Chaemsaithong P, Erez O Am J Obstet Gynecol. 2024; 230(3S):S807-S840.
PMID: 38233317 PMC: 11288098. DOI: 10.1016/j.ajog.2023.02.002.
Wilson G, Bondi D, Shah P, Nelson A, Kumar M, Bhagat P J Pediatr Pharmacol Ther. 2023; 28(4):316-322.
PMID: 37795280 PMC: 10547053. DOI: 10.5863/1551-6776-28.4.316.
Management of clinical chorioamnionitis: an evidence-based approach.
Conde-Agudelo A, Romero R, Jung E, Garcia Sanchez A Am J Obstet Gynecol. 2020; 223(6):848-869.
PMID: 33007269 PMC: 8315154. DOI: 10.1016/j.ajog.2020.09.044.
Venkatesh K, Leviton A, Hecht J, Joseph R, Douglass L, Frazier J Am J Obstet Gynecol. 2020; 223(5):745.e1-745.e10.
PMID: 32387324 PMC: 7609587. DOI: 10.1016/j.ajog.2020.05.001.
Antibiotic regimens for management of intra-amniotic infection.
Chapman E, Reveiz L, Illanes E, Bonfill Cosp X Cochrane Database Syst Rev. 2014; (12):CD010976.
PMID: 25526426 PMC: 10562955. DOI: 10.1002/14651858.CD010976.pub2.